Literature DB >> 17384320

Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease.

Kara A Bottiggi, Juan C Salazar, Lei Yu, Allison M Caban-Holt, Melody Ryan, Frederick A Schmitt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384320     DOI: 10.1097/JGP.0b013e31802dd354

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


× No keyword cloud information.
  5 in total

1.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

Review 2.  Routine deprescribing of chronic medications to combat polypharmacy.

Authors:  Doron Garfinkel; Birkan Ilhan; Gulistan Bahat
Journal:  Ther Adv Drug Saf       Date:  2015-12

Review 3.  Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia.

Authors:  Martin Taylor-Rowan; Olga Kraia; Christina Kolliopoulou; Anna H Noel-Storr; Ahmed A Alharthi; Amanda J Cross; Carrie Stewart; Phyo K Myint; Jenny McCleery; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

Review 4.  Anticholinergic Drugs in Geriatric Psychopharmacology.

Authors:  Jorge López-Álvarez; Julia Sevilla-Llewellyn-Jones; Luis Agüera-Ortiz
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

5.  INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol.

Authors:  Daniela C Moga; Brooke F Beech; Erin L Abner; Frederick A Schmitt; Riham H El Khouli; Ashley I Martinez; Lynne Eckmann; Mark Huffmyer; Rosmy George; Gregory A Jicha
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.